NEXT PICK · Market Insights
With a 500% surge within the year, how long can AEHR keep burning?
Wednesday, June 17, 2026
Yizhi Silicon Photonics placed additional orders and re-priced the stock price, but analysts' target prices were still 40% lower than the current price
What pushed AEHR into the trending list today wasn't the financial report or the collective rating upgrades by analysts, but a supplementary production order from a major Silicon Photonics client—a fully automated FOX-XP wafer-level burn-in system capable of testing nine wafers simultaneously, delivered within six months.
Following the news, this small company, with a market value of just over $3 billion, jumped 7.43% in a single day, closing at $112.62, and at one point surged to $123.48 during trading.
And this is only the surface
Pulling the lens, AEHR has risen more than 500% this year, with a cumulative increase of nearly 900% over the past twelve months, leaving the S&P 500 far behind.
Why is a company with a recent fiscal quarter revenue still down 44% year-on-year—being hailed by the market as the AI infrastructure shovel seller? Is this a real demand turning point, or just another bubble inflated by expectations?
|
Latest price
$112.62
▲ +7.43%
|
Year-to-date gains
Over 500%
▲ Nearly 900% in 12 months
|
Analyst target price
$64
▼ About 43% lower than current price
|
The semiconductor "oven quality inspector" is just catching the AI ride
AEHR was founded in Fremont, California in 1977, doing a job that sounds dull but is extremely crucial: wafer-level and chip-level testing and burn-in testing before chips leave the factory, filtering out defective products that might die young.
Its flagship product is the FOX series full-wafer test system, paired with the WaferPak Contactor, which supports 300mm wafer full-wafer contact—one of the few solutions in the industry that can "bake" entire wafers in one go, covering high-end scenarios such as silicon carbide power semiconductors, sensors, memory, and photonic devices.
If the chip is a high-speed engine, then AEHR is the extreme quality inspection that keeps the engine running continuously at high temperatures for dozens of hours before leaving the factory, focusing on faults. Previously, this business was lukewarm, with full-year FY2024 revenue of only $59 million, a year-on-year decline of 23%.
But the trend has changed. As AI computing power drives massive data center optical interconnect demand, silicon photonics transceivers and AI processors begin to require this rigorous aging test—AEHR happens to be stuck at the throat of this new track. The question is, can technical positioning wait until the order is fulfilled?
With a price-to-sales ratio exceeding 60 times, even bullish analysts think it's expensive
Let's first look at a set of glaring numbers
AEHR currently has a loss of about $0.38 per share, with a price-to-earnings ratio that is hard to discuss; The price-to-book (P/B) ratio reaches as high as 25 times, far exceeding the norm of 3 to 5 times for semiconductor equipment peers; The price-to-sales ratio (P/S) has surged to over 60 times, more than ten times the typical industry range.
A more blunt contrast lies with analysts—Wall Street rated it as "Buy," but the average target price was only about $64, more than 40% lower than the current price. Bulls all think this price is way too far ahead.
The research report's own cash flow discounted model also offers similar conclusions
The reasonable value in the neutral scenario is about $23 to $50, the upper limit in the optimistic scenario is just over $50, and the current price is $112.62.
So why is the market actually paying the price? The answer is the order and expectations, not the current profit statement. This approach of pricing growth for several years in advance once the pace of realization is slightly hesitant—how much room for drawdowns will there be?
The stock price has more than doubled above the 200-day moving average, betting on 2027
According to the report, AEHR is still in the early stages of transitioning from a "commercial pilot" to a "breakthrough eve": products have already been shipped in multiple end markets such as silicon photonics and silicon carbide power semiconductors, but the dual turning points for revenue and profitability have yet to be clearly established.
The technical aspect clearly describes the market's frenzy
The 50-day moving average is $92.18, the 200-day moving average is only $44.34, and the current price is $112.62—the stock price has already risen above more than twice the 200-day moving average. This means the market is not pricing in the status quo, but is heavily betting on FY2027 revenue acceleration. This confidence will have to be repaid step by step in the upcoming financial reports.
A narrow moat surrounded by giants
AEHR's competitors are each of astonishing numbers: Teradyne has a market cap of about $20 billion and revenue of about $7 billion; Japan's Advantest is also worth $20 billion, with deep penetration in Asian wafer fabs like TSMC and Samsung; Cohu has a more comprehensive layout in sorters and inspection equipment; The smaller inTEST is also facing it head-on in niche markets such as thermal testing.
AEHR's differentiation lies in its proprietary FOX-WaferPak 300mm full-wafer contact and FOX-CP low-cost single-wafer solution, which establish technical barriers in the narrow field of silicon photonics and silicon carbide aging tests.
But no one can say for sure how deep the moat is—the 10-K did not disclose specific patent numbers or validity periods, had highly concentrated clients, and lacked government orders or institutional endorsements to support it. This moat is more like a narrow and deep ditch: once a giant decides to acquire or develop its own products, how can AEHR hold its ground?
The ceiling isn't low, but the current market share is less than 1%.
Looking at the market, the global automated test equipment (ATE) market size is about $6 to $8 billion. AEHR's wafer-level test and power-added semiconductor and photonic device segments account for about 10% to 15% of this, corresponding to a market size of $6 to $1.2 billion.
The ceiling isn't exactly low, but AEHR estimates its actual market share is less than 1% based on annual revenue of less than $60 million. Its true growth potential lies in the long-term demand for AI data center optical interconnects and silicon carbide power devices—but for imagination to turn into orders, it takes time and must not be snatched away by giants.
The order book is telling you another story
If you only focus on declining revenue, you're missing out on what AEHR has recently truly changed the narrative—its order book and AI shift:
| ▲ Bull Case |
| ① | In the latest quarter, new orders exceeded $37 million, with a book-to-bill ratio above 3.5 times and effective orders on hand surpassing $50 million |
| ② | The company has raised its order outlook for the second half of the fiscal year to the upper end of the $60 million to $80 million range |
| ③ | In mid-April, it secured a production order worth about $41 million, and today it has added an additional order from a major Silicon Photonics client |
| ④ | The business focus has clearly shifted to the aging testing of AI processors and data center semiconductors, hitting the main line of computing power expansion |
| ⑤ | Management expects FY2026 to return to non-GAAP profitability in the fourth quarter, with FY2027 revenue likely to accelerate |
| ⑥ | Silicon carbide power semiconductors benefit from electric vehicles and industrial power supplies, while silicon photonics benefits from AI optical interconnects, with both long-term demand lines rising simultaneously |
Fundamentals have yet to catch up with the stock price
Bulls talk about the future, bears focus on the present—yet the current reports still look bad:
| ▼ Bear Case |
| ① | The most recently disclosed fiscal quarter revenue was only $10.3 million, down about 44% year-over-year, with gross margin dropping from 42.7% to 36.5% |
| ② | The company has yet to achieve profitability under U.S. GAAP, with a loss of about $0.38 per share over the past twelve months |
| ③ | Free cash flow has been negative for a long time, with seven out of eight quarters under the report being negative, indicating that self-sustaining ability has yet to be established |
| ④ | With a price-to-sales ratio of over 60 times and a price-to-book ratio of 25 times, the valuation is far from any traditional anchor point |
| ⑤ | The average Wall Street target price is about $64, more than 40% below the current price, and even bulls do not agree with the current price |
| ⑥ | The additional order amount for Ignite today was not disclosed, making the value of the order difficult to quantify |
| ⑦ | The Beta is as high as 3.18, the stock price has more than doubled the 200-day moving average, heavily dependent on a few major clients, so the pullback will not be gentle |
Three time windows determine where to burn the fire
In the coming months, AEHR's stock price will be dominated by three types of events: whoever pays first will have the say in the next phase:
| • | FY2026 Q4 financial report in early July: Whether management can fulfill its promise to "return to non-GAAP profitability" is the most critical hurdle |
| • | The six-month delivery window for additional Silicon Photonics orders, and whether the customer will continue to place additional orders within the year as expected |
| • | The pace of demand for AI processors and data center aging testing will determine whether FY2027 revenue can truly accelerate |
From $40 to $112, a frenzy driven by expectations
Looking at the timeline, AEHR's recent rally has been remarkably fierce: the 200-day moving average is still at $44.34, the current price is $112.62, up nearly 900% over the past twelve months and over 500% this year.
The driving force is clear and discernible—the AI investment boom combined with the rise of the silicon photonics concept has repriced this small-cap testing equipment company as an "AI shovel seller," and the strong rebound in the order book has added fuel to the story.
The paradoxical part is here
During the same period, revenue continued to decline year-over-year, and GAAP profit had yet to turn positive. The stock price is far ahead of the fundamentals; the market is betting on a turning point, but the turning point has yet to be stamped by earnings. How long this divergence lasts often does not depend on the company, but rather on how long the market is willing to pay a premium for "expectations."
|
⚠️ Risk Notice It is important to clearly recognize that AEHR's biggest current risk comes precisely from its greatest appeal—expectations: revenue continues to decline sharply year-over-year, GAAP earnings have yet to be realized, and the stock price has already exhausted optimistic assumptions for the coming years. If order deliveries fall short of expectations or AI demand cools, a price-to-sales ratio of over 60 times combined with a high beta of 3.18 could trigger a drawdown that could be both fast and deep; Meanwhile, the company is highly dependent on a few major clients, the amount of additional orders is not disclosed, and free cash flow has been negative for a long time. Any problem in any link could amplify volatility. This article is solely based on analysis and information sharing based on publicly available information and does not constitute any investment advice. The market carries risks, so decisions should be made cautiously. Please make independent judgments and bear your own risks. |
|
🟡 Neutral Orders and AI expectations have been heavily factored into the stock price, but fundamentals have yet to catch up with the current price |
|
💬 Discussion Do you think AEHR is AI infrastructure, or just another bubble that's been inflated? |
Data source
| • | Latest price, market capitalization, price change, 12-month and year-to-year gains: Stocktwits "Why Is AEHR Stock Surging Today?" (2026-06-17) — https://stocktwits.com/news-articles/markets/equity/why-is-aehr-stock-surging-today-june-17-2026/cZK0UC2R7It |
| • | Details of Silicon Photonics Additional Order and CEO Statement Today: Yahoo Finance / Investing.com Report — https://finance.yahoo.com/technology/ai/articles/aehr-test-systems-shares-climb-130403612.html |
| • | Recent Fiscal Quarter Revenue/EPS/Gross Margin, Order and Reversion to Profitability Guidance: Investing.com Q3 FY2026 Financial Summary — https://www.investing.com/news/transcripts/earnings-call-transcript-aehr-test-systems-q3-2026-reports-mixed-results-93CH-4601816 |
| • | Analyst ratings and average target price, April $41 million orders, second half of fiscal year orders: MarketBeat / Public.com forecast page — https://www.marketbeat.com/stocks/NASDAQ/AEHR/forecast/ |
| • | Stock Analysis — https://stockanalysis.com/stocks/aehr/ |
---
A verification tip for you (not part of the main article, so you can confirm before publishing):
1. I did not use the "Q1 2026 revenue $10.3M" label from the research report — after verification, that was actually the data from Q3 FY2026 (revenue $10.3M, year-on-year −44%, EPS −$0.05 exceeding expectations, gross margin 36.5%). The quarterly label in the research report was incorrect; the article was rewritten according to the publicly available financial report. 2. The report treats the silicon photonics order as an "unverified Reddit rumor (conviction 7/10)"—actually a real additional order confirmed by company press release/media. Today's anomaly catalyst is real and undisproven, but the order amount was not disclosed. I truthfully pointed out this uncertainty in bear-thesis. 3. Research report misses core bullish evidence: record order book (new quarterly > $37 million, book-to-bill >3.5x, orders on hand >$50 million), April orders $41 million, shift to AI processor/data center aging testing, and guidance for a return to profitability in Q4 FY2026. These have been added to the article. 4. live_data's "Analyst Target Price Pending" has been supplemented with publicly available data: Consensus "Buy" rating, average target price about $64, about 43% below the current price — this is the strongest anchor for the article's neutral stance. 5. Regarding "Has the positive news been realized": The stock price has risen +500% year-to-date, far above analysts' target prices and its own 200-day moving average. The article clearly states in multiple sections of valuation, stance, and history that "expectations have been significantly price-in."